Fig. 4

Vascularization and lymphatic drainage of healing wounds. (a) Immunohistochemical detection of CD31⁺ microvessels in a PRP-treated and a PRP + NF-treated wound on day 14. (b) Microvessel density (mm^− 2) of PRP-treated (white bars; n = 8) and PRP + NF-treated (black bars; n = 8) wounds on day 14, as assessed by immunohistochemistry. Mean ± SEM. (c) Immunohistochemical detection of CD31⁺/GFP⁻ (arrows) and CD31⁺/GFP⁺ (arrowheads) microvessels in a PRP + NF-treated wound on day 14. (d) CD31⁺/GFP⁺ microvessels (%) in PRP + NF-treated wounds (black bar; n = 8) on day 14, as assessed by immunohistochemistry. Mean ± SEM. (e) Immunohistochemical detection of LYVE-1⁺ lymph vessels in a PRP-treated and a PRP + NF-treated wound on day 14. (f) Lymph vessel density (mm^− 2) of PRP-treated (white bars; n = 8) and PRP + NF-treated (black bars; n = 8) wounds on day 14, as assessed by immunohistochemistry. Mean ± SEM. (g) Immunohistochemical detection of LYVE-1⁺/GFP⁻ (arrows) and LYVE-1⁺/GFP⁺ (arrowheads) lymph vessels in a PRP + NF-treated wound on day 14. (H) LYVE-1⁺/GFP⁺ lymph vessels (%) in PRP + NF-treated wounds (black bar; n = 8) on day 14, as assessed by immunohistochemistry. Mean ± SEM.